What are the new medical insurance drugs with 2,800 "must talk" drugs? Let's see together →
Today (March 1), the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug List (2020)" was officially implemented nationwide. The list of drugs reached 2,800, basically achieving full coverage in the treatment field.
According to the National Medical Insurance Administration, the total number of drugs in the adjusted "Drug List 2020" is 2,800, of which 1,426 are Western medicines and 1,374 are Chinese patent medicines.
Compared with previous years, in 2020, the medical insurance catalogue has the largest number of drugs transferred, and the scope of benefits is the widest. The newly transferred 119 drugs involve 31 clinical groups.
Since then, my country's medical insurance catalogue has covered 52 treatment areas with Chinese and Western medicines, and 31 treatment areas with Chinese medicines, basically achieving full coverage of treatment areas.
Especially in the fields of tumors, cardiovascular and cerebrovascular diseases and immune system diseases, it has filled many medication gaps and better met the basic medication needs of insured persons.
"Must talk about every advance" medical insurance catalog structure is more optimized
At present, my country's exclusive drugs for the treatment of serious and serious diseases are included in the catalog mainly through negotiation, which is "talking about every advance."
After three years of medical insurance catalogue negotiations, how many kinds of drugs did we buy?
In the negotiation of the National Medical Insurance Catalogue, in 2018, 2019, and 2020, 17 medicines, 70 medicines, and 96 medicines were negotiated, and the price drops were 56.7%, 60.7%, and 50.64%, all reaching more than half.
After multiple rounds of adjustments, the medical insurance catalog structure has been optimized and the medication levels have become more abundant.
Before the catalogue adjustment, more traditional chemotherapy drugs, such as paclitaxel and pemetrexed.
After adjustment, a large number of innovative targeted drugs and tumor immune drugs are included in medical insurance.
Including 7 targeted drugs osimertinib (negotiation access in 2018, successful contract renewal in 2020), erlotinib (negotiation access in 2019), ametinib, anlotinib, crizotinib, Ceritinib, Aletinib (access to negotiations in 2020).
There is also a tumor immune drug: Carrelizumab (negotiation access in 2020).
Ding Jinxi, Executive Deputy Dean and Professor of the Graduate School of China Pharmaceutical University: For the
same indication, the same disease, its varieties are relatively rich, and the varieties are updated relatively quickly.
After the new drugs are on the market, the speed of entering medical insurance is relatively fast.
Not only have prices dropped, but the time taken for innovative drugs to go from the market to the time they are included in medical insurance has also been greatly shortened.
The median time from listing to entering medical insurance for drugs negotiated in 2020 is 1.8 years.
Some drugs were even launched in July of that year and were included in the medical insurance in December, with an access period of only 5 months.
Xiong Xianjun, Director of the Medical Service Management Department of the National Medical Insurance Administration: Judging
from the adjustments in the past few years, the varieties we have
imported
are still much less than those
imported
, although these drugs are all after a substantial price reduction. It was transferred in, but as far as the fund is concerned, its expenditure is still growing.
From the statistics of relevant departments in recent years, the cost of medicines paid by the medical insurance fund is still absolute year by year, and the overall increase, but the increase is gradually decreasing.
AIDS, hepatitis C and new coronary pneumonia medications are included in medical insurance
In the 2019 and 2020 medical insurance catalog adjustments, 4 AIDS drugs, 4 hepatitis C drugs, and 2 drugs for the treatment of new coronary pneumonia have been added to provide support for normalized epidemic prevention and control.
The four companies calculated on-site and directly quoted prices. In the end, Gilead’s Ladipave Sofosbuvir and Merck’s Elbawe Glarevir reduced prices by 89.87% and 90% respectively.
The price reduction of medicines for more than a year has brought any changes to clinical work?
Jia Jidong, former chairman of the Chinese Medical Association Hepatology Branch:
When choosing drugs, there was a concern about price in the past, but now no matter from doctor to patient, this concern basically
disappears
.
These original research drugs went from more than 1,000 yuan a month to generic drugs later, and they were also several hundred yuan a month. Now they should be less than ten yuan a month. This range is quite large. Basically, from an economic point of view, there are no barriers to treatment.
The doctor said that in the past when choosing drugs, he knew that there were some good treatment options, but the cost was too high for the patient, and it might be necessary to choose some sub-optimal treatment options. Now the doctor can choose according to the patient’s condition. Choose a favorable treatment plan.
The World Health Organization issued a report specifically for this purpose, stating that China has drastically reduced the cost of prevention and treatment of viral hepatitis and has significantly improved the accessibility of treatment for patients.
There are medicines to treat patients who really benefit
The medical insurance catalogue has been adjusted for three consecutive years. In what ways do we ordinary people have more protection?
Lu Yong, suffering from chronic myelogenous leukemia, needs to take the anti-cancer drug "Gleevec" all the year round, so how is his life now?
Lu Yong:
It was diagnosed in August 2002. By this year, it has entered its 19th year.
For 19 years after his diagnosis, Lu Yong himself did not expect that the anti-cancer drug "Gleevec" used to maintain his treatment would cost 20,000 yuan a month before 2018.
Now the original research drugs and generic drugs are included in the medical insurance reimbursement.
Lu Yong:
(Now) It is 1197 yuan per month.
Then, if it is a domestic generic drug, the drug has now entered the centralized procurement.
For centralized procurement, the price is more than 1,200 per month.
Then the medical insurance will cover a part of it, which may cost a few hundred dollars.
The drug purchase group established in the past has become a communication group for greetings and fitness check-in among patients.
When the disease becomes curable and the people can afford it, more people have returned to normal lives like Lu Yong.